N
Google TrendLAMINE YAMAL (2000+) — "You want to play for Morocco?": Getafe defender provokes Yamal with shocking words
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lamine yamal2000+abdulrahman alfozan500+pope francis500+olise500+delaware vs middle tennessee prediction500+bayern de múnich200+gme1000+flashscore200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Isatuximab Boosts MRD Neg" (13 stories)

Top Headline Story

Iberdomide Pairs With Isatuximab to Rescue MRD-Positive Patients After Transplant
Lead StoryPharmacy Timestech
Sep 24

Iberdomide Pairs With Isatuximab to Rescue MRD-Positive Patients After Transplant

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNTl8zZjZRTW5odU1CaGlqdDRhLXFVZWVOajExbnF4YjVkYkRFY1NWU1lseUxSLW1oYTdQcHkzTUVVd1J0bi0yVmlnWEJLc2UyNFZVNFI3WEQ0VFFBNk9FYjc3WEFCQmE5ZWRTRkpkUU84V3ZoY19UaV9IcTlPVTNqRjhzdmpWNnNhWEcxVllHRmx3cFpHX3NsLUNLQkloalpfMnowelN2MmoyTEdzbERDcGRTOUlsaFE?oc=5" target="_blank">Iberdomide Pairs With Isatuximab to Rescue MRD-Positive Patients After Transplant</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+22m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories
500+32m ago

abdulrahman alfozan

OpenAI engineer arrested in bugging of executive conference room

Filter stories
500+32m ago

pope francis

The Myth of St. Francis

Filter stories
500+32m ago

olise

Bayern’s Michael Olise sent off for 2 yellow cards within seconds in Champions League

Filter stories

Search Results for "Isatuximab Boosts MRD Neg"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

12 stories displayed
Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma
Targeted Oncologytech

Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQTjhGTDNEY2FDNnd4aV8zeVFPOVktOHpaMGNMWDZZS2d0Vk1CclVSOVNDR090aFJNRVhrSnRpb19XdHRfd084UFcxMG00dFptODJWZk9xYU5HU0dWZmlQaVVidkZsT2dHZnZpMjV4dDU4Wk5CVVNGUTk4eVJCbU1FZUQ5ak9pU3lrMDR1eXdVVmFrdXhjZnFyc1hvMDhpUHMxby1NLXR6MTVsaXRIZXc?oc=5" target="_blank">Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Combination Treatment May Improve Multiple Myeloma Outcomes
Medscapegeneral

Combination Treatment May Improve Multiple Myeloma Outcomes

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPVi1zMElXYTN0SUpQMng2TDQxa3hDRVlVM1IzOUlGUlFFTEltNHgtQUJZbC1yLXIwdk1DRVVfeTR1ZWExelRUUy1PazJVdXN4cGRfNTc5LTgxN2Y0NEFFbVVUQWZyWkQyckhzQ1pleUVBdFNzLVZkcUtKSExKQ013b1ZOM2I2U3Q2aXFSWnVCdmI0dEtFZS1pZXlWdHZMOXNiTXVveUlqYl83emVYMEE?oc=5" target="_blank">Combination Treatment May Improve Multiple Myeloma Outcomes</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma
OncLivetech

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOdUVyMXBmNHp2Ykl4R3JKX0lmaktwbkI1eE83ZUNuRmFNUFlONmlwOE83aVhyblFmZjM1UjlCb0NRdTNMZkktdmdEaWFIOThJcEh2akM3T3lZNHZidFFwbUkzTWxsSzdIczVEZ2Q5TEFsUFRRWVNCX1hvNFBfcWRVcm5rSDVTUGNZQWhzSTVSZWxadUZWUUNMRGpIOXlpNGc?oc=5" target="_blank">Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
ASH 2023: Coverage in Multiple Myeloma
The American Journal of Managed Caregeneral

ASH 2023: Coverage in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE5FR2RoN1ExTldzMUlwMkkwdkpaQk9teUZ5TDMyZG1ad2FrSVlxMUo1ZUlTcGwyRlpQLXNuT2VoWDBVWWFXeXlOWmZtbXM5ZWVpQ1g4T3UtX1ZQNndGN2JjSjJ6VmNLQk5hRGlVNVRYcEs?oc=5" target="_blank">ASH 2023: Coverage in Multiple Myeloma</a>  <font color="#6f6f6f">The American Journal of Managed Care</font>

Read Full StoryMore like this
ASH 2025: Updates in Multiple Myeloma Treatment and Outcomes
Hematology Advisorgeneral

ASH 2025: Updates in Multiple Myeloma Treatment and Outcomes

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQNjJmSjhQaWUwc1VKejNTQTV6OUgzanZXbDkyeWMzdEZsZTlpRWZrMFZLZXBwUzVfeThfa01pOEtDcmZIMWVnNjllUEdrUjhsTmxNMnZ0NU1MOU9wcUpZbWNna21TdUMyeW5mSlVoR3M2NllQSF9FQVFtVzRZUW5vOXZOVWFRTGRGQ3lYbTNjOXJZT3pYejhDTjhiVWZOaDVoSUE?oc=5" target="_blank">ASH 2025: Updates in Multiple Myeloma Treatment and Outcomes</a>  <font color="#6f6f6f">Hematology Advisor</font>

Read Full StoryMore like this
Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
Pharmacy Timesgeneral

Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOcVlCXzAxZDkzYzhOUWFZRmhNNXVxamhINmxXTTlNMGNKcjVvOUpjZ2N6OXNKbmthS3JvaVRuNXVabXpoQ2QwbDRxRlNfLXRZa2pzcVlicTRuQWdQT1ZsV3RXWURJN0I2OHE4bFBaN1R6bmlidWdkN1hQaWtLYlRsVVlXYndreHUzVEl1TDhhTXdTaWVkTzRBNlZwZEJ0SkRqYnlJMml3NmtpVk1qeTVCZUNUQkJvY05fY0RraExMTGVIUQ?oc=5" target="_blank">Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT
OncLivetech

Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPVDdkd3dzb2hhTkpmc2FZRDNJTmJIcmo2MEFXSnVHcVlSSHF2Y0VFb1U0YklqQV96eExQT3JNWTJNSU9yRnhLNVlxekI1c01SaHpFVFpwN2F1YXNoVG1HcE0wMlpiYkRhczNwNTFMZXExeHJNMVNtTVJaR05RTDdrR1hQbXFRbFRnQXJPcnd1N0lrMVkxYU5LLXc5QlJReVQzbGFCMW1WMF9iX3hCU1doanpkSFRxSXFvQWdMUmVORGtWRHQwekxGRm0zRUFldw?oc=5" target="_blank">Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma
OncLivegeneral

Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQcXZDVUpoeFBkc21aZUVPTXJaWkdPV09IbDlaOHlSc1BOQnFPVzFPVUc4WFpWcVNlUVdVXzF3cDlXY2R2X1RXSUJHLTVLZXo1azVqVzRMX3AwaVpLNUVLMk1nU1hoNVROTHFRZ3BxNDhqbmFYS2lPRHJMZmctYWNPZmR5Q1lidllhclV2QWEtczg3a29PSDlmeUY2Ri1lbnFoRjc2bVU2a3dVdkNKSDVZcFBwbFEyZw?oc=5" target="_blank">Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma
Pharmacy Timesgeneral

Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOLTNDYVlVMXpJZWZ3UFlMQUJpZFFxZ01nRll4T1Q4OWNJdUZQWXhJdHhVdkNNbUY3UXNjR1FyQ0VXU3JOUjlLWDBjSHdQbFVzb1NxTnFEOEVtYlFCanpFclQtX0pfRkFGeXlGeTVCZklVcFhMQ0NVS1ZfSUs3UTNhSVdhQ1FIZXN2UlN3aERObjNVUHl6N01wTGswSWJOOWhNZnR4b1pkNGY3bG12YlBrWi1ic3Nqc1ctVm5qMFhR?oc=5" target="_blank">Quadruple Therapy With Isatuximab Shows Promise for Older Adults With Multiple Myeloma</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Isa-VRd Prolongs PFS in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
OncLivegeneral

Isa-VRd Prolongs PFS in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcFpxOGY1czdMYWpzRHNPMTZiV3BpdnZOdGxIb0RrR0NVUmN0SWVVLVk3NTdvRERQQUlmSnQ2Skxxa0xZY3gzZzhDR2R3dGJxUnoxS2p3UmY4Wlp4RW1Wd2JqcldTUXpOdjVxR25EM0czRlZ1ZVBlUVllaUNObks3ZW94VWtFRlgwRGN6bFVsUkN0MUNRTkZlR05Lb1U0RXVfV0llZzNWd0xfYjA?oc=5" target="_blank">Isa-VRd Prolongs PFS in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Study: Immune-Boosting Antibody Treatment Isatuximab Meets Primary Endpoint for Multiple Myeloma
Pharmacy Timesworld

Study: Immune-Boosting Antibody Treatment Isatuximab Meets Primary Endpoint for Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOOW5JNmhDQXVVMldvcTFxZk9IV2hLOVZGQUFFdXpNTW1KdlBoMUNRMklZNDF6bTQ1YmRLR09IZ2gzUHhzc0hSN1QzczVUWXlXSHcyNDFyQ1F2UHNkd0l1VXpiVjhHa0k5a19TOEpveGNtLVpLYzVPeGJzQVhnTmlUUWxFZENHaDhUdDJCbUg3dUlCSVdIZzJVb0pkOEVoSzZZa0pMWHFQdWVSY1hLcUhCNFZjckctbU5rdXhXRWg4UDVxRUR4UVkyWjd3?oc=5" target="_blank">Study: Immune-Boosting Antibody Treatment Isatuximab Meets Primary Endpoint for Multiple Myeloma</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
How Can the New Definition of Epilepsy Improve Patient Outcomes?
Pharmacy Timesgeneral

How Can the New Definition of Epilepsy Improve Patient Outcomes?

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQYmxzUlNVWm5aQTFUcGRJMHlVdEJySDhLbF9uMGM5YVJEM1pMRnA2aVZNZ0VDWm90THFUdzVZZl9COXRGSV9NUlViVHhoQ0RzU3RSbUFZdHFSeTJIeGtGUzNuNlNvOVdQNHBqMDd1ZFpuNFlGWF9UdmpzbzJrX1NKQU90blRtblZKZkowblJyMW5pSEw3UC1aRzNXZTBzY1VG?oc=5" target="_blank">How Can the New Definition of Epilepsy Improve Patient Outcomes?</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
"Isatuximab Boosts MRD Neg" — Live Google News Trends & Headlines